Weekly dosing, and why
Retatrutide has a long half-life, roughly five to six days based on published pharmacokinetic data, which is why it’s dosed once a week rather than daily. A weekly injection keeps blood levels in a fairly steady range instead of spiking and falling the way a short-acting drug would.
Building to steady state
It takes about four to five half-lives for a drug to reach steady state, the point where the amount going in each week roughly matches the amount clearing out. For retatrutide, that lands close to the four-week mark, which is also why most titration schedules hold each dose step for about that long before moving up.
Why titration exists specifically for this drug
Retatrutide activates three separate receptors: GLP-1, GIP and glucagon. Each one affects appetite, digestion or metabolism slightly differently, and the combined effect at a full dose is stronger than any one receptor alone would produce. Titration spreads the introduction of that combined effect over months instead of one week.
What the receptors actually do
GLP-1 slows gastric emptying and increases the feeling of fullness. GIP works alongside GLP-1 on insulin release and appears to affect fat tissue directly. Glucagon receptor activity increases energy expenditure, which is the receptor retatrutide has that semaglutide and, to a lesser extent, tirzepatide don’t strongly engage.
Why this matters for a titration schedule
Because the effect comes from three receptors rather than one, the adjustment period at each dose step tends to involve more than just appetite changes, which is part of why patience with the schedule is repeatedly emphasised in trial follow-up data and community reporting alike.